The Journal of Rheumatology · 2017 · 12 citations · 37 references
MedicineImmunologyPediatricsMonoclonal AntibodiesPediatric RheumatologyRheumatologyAutoantibodiesAutoimmune Rheumatic DiseasesImmunogenicity Of Therapeutic AntibodiesInflammatory ArthritisPediatric UveitisRheumatoid ArthritisDocumentation Of Infusion ReactionsHypersensitivity Reactions To Therapeutic AntibodiesInfusion-related ReactionsMean Response TimeRefractory Rheumatoid Arthritis
OBJECTIVE: Infliximab (IFX) is a monoclonal tumor necrosis factor-α-inhibiting antibody used in children with refractory arthritis and uveitis. Immunogenicity is associated with a lack of clinical response and infusion reactions in adults; data on immunogenicity in children treated with IFX for rheumatic diseases are scarce. We aimed to describe the prevalence of anti-IFX antibodies and determine co-factors associated with anti-IFX antibodies in children with inflammatory rheumatic and ocular diseases. METHODS: Consecutive children treated between August 2009 and August 2012 with IFX at our department were included. Blood samples were collected every 6 months before IFX infusion and tested for anti-IFX antibodies by radioimmunoassay. Patients' charts were retrospectively reviewed for clinical features and analyzed for associations with anti-IFX antibodies. RESULTS: Anti-IFX antibodies occurred in 14/62 children (23%) and 32/253 blood samples (12.6%) after a mean treatment time of 1084 days (range 73-3498). Infusion reactions occurred in 10/62 (16%) children during the treatment period. With continuation of IFX, anti-IFX antibodies disappeared in 7/14 children. In the bivariate analysis, the occurrence of anti-IFX antibodies was associated with younger age at IFX treatment start (mean age 7.01 vs 9.88 yrs, p = 0.003) and infusion reactions (OR 15.0), while uveitis as treatment indication was protective against development of anti-IFX antibodies (OR 0.17), likely because of higher IFX doses. In the multivariate logistic regression, all 3 covariates remained highly significant. CONCLUSION: Anti-IFX antibodies occurred commonly at any time during IFX treatment. Anti-IFX antibodies were associated with younger age at IFX start, infusion reactions, and arthritis as treatment indication.
37
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet · 2002 · 4.2K citations
Ravinder N. Maini, Ferdinand C. Breedveld, Joachim R. Kalden et al. · Arthritis & Rheumatism · 1998 · 1.6K citations
Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997
Ross E. Petty, T. R. E. Southwood, John Baum et al. · 2001 · 1.2K citations
Preliminary definition of improvement in juvenile arthritis
Edward H. Giannini, Nicolino Ruperto, Angelo Ravelli et al. · Arthritis & Rheumatism · 1997 · 1.1K citations